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Abstract
Background: Owing to their important function in regulating cell death, pharmacological inhibition of Bcl-2 proteins by
dubbed BH3-mimetics is a promising strategy for apoptosis induction or sensitization to chemotherapy. However, the role
of Apaf-1, the main protein constituent of the apoptosome, in the process has yet not been analyzed. Furthermore as new
chemotherapeutics develop, the possible chemotherapy-induced toxicity to rapidly dividing normal cells, especially
sensitive differentiated cells, has to be considered. Such undesirable effects would probably be ameliorated by selectively
and locally inhibiting apoptosis in defined sensitive cells.
Methodology and Principal Findings: Mouse embryonic fibroblasts (MEFS) from Apaf-1 knock out mouse (MEFS KO Apaf-1)
and Bax/Bak double KO (MEFS KO Bax/Bak), MEFS from wild-type mouse (MEFS wt) and human cervix adenocarcinoma
(HeLa) cells were used to comparatively investigate the signaling cell death-induced pathways of BH3-mimetics, like ABT737
and GX15-070, with DNA damage-inducing agent cisplatin (cis-diammineplatinum(II) dichloride, CDDP). The study was
performed in the absence or presence of apoptosis inhibitors namely, caspase inhibitors or apoptosome inhibitors. BH3-
mimetic ABT737 required of Apaf-1 to exert its apoptosis-inducing effect. In contrast, BH3-mimetic GX15-070 and DNA
damage-inducing CDDP induced cell death in the absence of both Bax/Bak and Apaf-1. GX15-070 induced autophagy-based
cell death in all the cell lines analyzed. MEFS wt cells were protected from the cytotoxic effects of ABT737 and CDDP by
chemical inhibition of the apoptosome through QM31, but not by using general caspase inhibitors.
Conclusions: BH3-mimetic ABT737 not only requires Bax/Bak to exert its apoptosis-inducing effect, but also Apaf-1, while
GX15-070 and CDDP induce different modalities of cell death in the absence of Bax/Bak or Apaf-1. Inclusion of specific Apaf-
1 inhibitors in topical and well-localized administrations, but not in systemic ones, to avoid interferences with
chemotherapeutics would be of interest to prevent chemotherapeutic-induced unwanted cell death which could improve
cancer patient care.
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Introduction
Current anti-tumour treatments based in inducing apoptosis
target cancer cells and rapidly dividing normal cells as well as
other especially sensitive differentiated cells. Therefore, these
treatments do not differentiate between malignant and normal
cells. Chemotherapy causes toxicity, leading to side effects like
those reported for apoptosis-inducing and DNA-damaging agent
cisplatin (cis-diammineplatinum(II) dichloride, CDDP), which
induces ototoxicity [1] and alopecia [2]. These undesirable effects
may be ameliorated by the discovery of new more specific cell
death-inducing drugs [3], or by selectively and locally inhibiting
apoptosis in defined sensitive cells.
The discovery of the components of the apoptosis signaling
pathway is providing the basis for novel targeted therapies that can
induce death in cancer cells. Then BCL-2 antagonists as the
chemotherapeutical drugs called BH3-mimetics are in clinical
phase II [4]. On the other hand, apoptosis inhibitors-based drugs
may have the potential to locally attenuate chemotherapy-induced
side effects if the effective dose of apoptosis inducer (chemother-
apeutic drug) versus apoptosis inhibitor is defined. Current
synthetic apoptosis inhibitors include caspase inhibitors [5] and
apoptosome inhibitors [6].
The proposal of developing BH3-mimetics as chemotherapeutic
drugs originates from understanding the role of the Bcl-2 protein
family in regulating the intrinsic apoptotic pathway by controlling
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mitochondria outer membrane permeability (MOMP). The anti-
apoptotic members of this family (Bcl-2, Bcl-xL, Bcl-W, Mcl-1 and
A1) are characterized by the homology of four regions denomi-
nated Bcl-2 homology domains (BH1, BH2, BH3 and BH4), pro-
apoptotic members, Bax, Bak and Bok, which share domains
BH1-3, while the BH3-only proteins (e.g., Bad, Bid, Bim, Noxa
and Puma) contain only the BH3 region [7]. BH3-only proteins
promote apoptosis by suppressing anti-apoptotic proteins at the
mitochondria and the endoplasmic reticulum or by directly
activating Bax and Bak [8]. The anti- and pro-apoptotic balance
of Bcl-2 proteins is deregulated in cancer cells [9]. Extensive work
was performed to elucidate the process whereby protein-protein
interactions between Bcl-2 protein family members commit cells to
apoptosis. As a unified model, and under homeostatic conditions,
anti-apoptotic Bcl-2 family members present a hydrophobic
groove that interacts with the BH3 domain of pro-apoptotic
effectors (Bax and Bak) or the BH3-only proteins to allow their
sequestration, as well as the inhibition of MOMP. Apoptotic
stimuli release Bax and Bak from the hydrophobic groove to
induce oligomerization at the mitochondria membrane and
MOMP. Therefore, cytochrome c (Cyt c) and Smac/Diablo
proteins are released from the mitochondrial intermembrane
space [10]. Cyt c binds to apoptosis protease-activating factor-1
(Apaf-1) to induce apoptosome assembling that recruits and
activates initiator caspase-9, which further activates effector
caspases, inducing apoptotic cell death [11].
The small molecule compounds developed as inhibitors of anti-
apoptotic Bcl-2 proteins, generically named BH3-mimetics such as
ABT737 (Abbott Laboratories) or obatoclax (GX15-070, Gemin
X Biotechnologies), release pro-apoptotic binding partners and
suffice to induce apoptosis. ABT737 binds selectivity to anti-
apoptotic Bcl-2, but has a low affinity to Mcl-1 and A1 [12,13].
GX15-070 has been proposed to influence the activity of the Bak/
Mcl-1 and Bim/Mcl-1 complexes [14] to induce mitochondrial-
mediated apoptosis, which would imply Bax/Bak-mediated
MOMP and apoptosome-mediated activation of caspases. How-
ever, in some cell lines that are relevant for disease, GX15-070-
treatment has also been described to render phenotypic cell
characteristics which could be associated with GX15-070 activi-
ties, including autophagy, independently of mitochondrial-medi-
ated apoptosis. The cytotoxic activity of GX15-070 and ABT737
in Bax/Bak double knockout cells has also been reported [15,16],
while the role of the apoptosome is unclear as it is still to be
explored in detail. This is particularly relevant for studying the
activity of BH3-mimetics in cells with low Apaf-1 contents that
correlate with resistance to chemotherapeutic treatments [17,18]
and for preclinically evaluating a new class of apoptosis inhibitors
targeting the apoptosome [19,20], which are currently being
evaluated as agents to locally prevent chemotherapy-induced
secondary effects. It would then be of interest to comparatively
analyze the activity of BH3-mimetics and CDDP (as a represen-
tative of established cytotoxic drugs) in cells in which Apaf-1 has
been genetically deleted and to also analyze whether apoptosome
inhibitors can inhibit BH3-mimetics-induced cell death.
Here we analyzed the ability of BH3-mimetics GX15-070 and
ABT737 to induce cell death in mouse embryonic fibroblasts
(MEFS) from Apaf-1 knockout (KO) mouse (MEFS KO Apaf-1)
and in MEFS from wild-type mouse (MEFS wt) in the presence
and absence of the apoptosis inhibitors Z-Val-Ala-Asp(OMe)-
fluoromethylketone (zVADfmk – a general caspase inhibitor [5])
and QM31, an apoptosome inhibitor [19,20]. The results were
comparatively evaluated with the effects of CDDP under the same
experimental conditions and were extended to MEFS from Bax/
Bak double KO mouse (MEFS KO Bax/Bak) and to human
cervix adenocarcinoma (HeLa) cells.
Materials and Methods
Cell culture, treatments and chemicals
ABT737 and GX15-070 were from Abbott Laboratories and
from SelleckBio, respectively; cis-diammineplatinum(II) dichloride
(cisplatin, CDDP), rapamycin and 3-methyladenine (3MA) were
obtained from Sigma Aldrich. QM31 is a perhydro-1,4-diazepine-
2,5-dione whose general synthetic method has been recently
reported [21]. The HeLa cell line was purchased from ATCC, and
MEFS [22,23] were provided by Dr. Guido Kroemer (MEFS wt
and KO Bax/Bak) and Dr. Francesco Cecconi (MEFS wt and KO
Apaf-1). All the cell lines were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS). Cultures were maintained at 37uC in a 5% CO2
atmosphere. Cell media and FBS were purchased from GIBCO
BRL Life Technologies. When indicated, cells were treated with
1 mM of GX50-070, 25 mM of ABT737, 30 mM of rapamycin and
30 mM of CDDP. When required, 10 mM MA, 10 mM QM31 or
5 mM zVAD were administered 30 min after treatment addition,
and cells were maintained in culture for 24 h. Assays were carried
out between passage 6 and 10, in all cases.
Determination of caspase activity
All cell extracts were prepared from 1.56105 cells seeded in 6-
well plates. After 24 h, cells were treated as indicated above and
were then scrapped and washed with PBS. Pellets were
resuspended in extraction buffer (50 mM PIPES, 50 mM KCl,
5 mM EDTA, 2 mM MgCl2, 2 mM DTT) supplemented with
protease inhibitor cocktail (Sigma) and kept on ice for 5 min. Once
pellets were frozen and thawed three times, cell lysates were
centrifuged at 14000 rpm for 5 min and supernatants were
collected. Quantification of the total protein concentration was
performed using the BCA protein assay (Thermo Scientific). Total
protein (50 mg) was mixed with 200 mL of caspase assay buffer
(PBS, 10% glycerol, 0.1 mM EDTA, 2 mM DTT) containing
20 mM of the Ac-DEVD-afc (Enzo Life Sciences) caspase-3
specific substrate. Caspase activity was continuously monitored
following the release of fluorescent afc at 37uC using a Wallac
1420 Workstation (lexc = 400 nm; lem=508 nm). Caspase-3
activity was expressed as the increase of relative fluorescence units
per min (A.U.).
Flow cytometry
After drug treatment, the cell culture medium was collected to
retain floating cells and attached cells were dislodged using 0.5%
Trypsin-EDTA (GIBCO). Floating and attached cells were
combined and harvested by centrifugation. The cell pellets were
suspended in 100 ml binding buffer (10 mM HEPES pH 7.4,
Figure 1. Apaf-1 inhibitor QM31 prevents cell death in non tumor cells treated with both ABT737 and CDDP, but not in cells treated
with GX15-070. (A and D) Caspase 3-like activity was measured in MEFS wt Apaf-1 and MEFS wt Bax/Bak treated with ABT737 (25 mM), GX15-070
(1 mM) and CDDP (30 mM) in the presence or absence of QM31 (10 mM) and zVADfmk (5 mM). (B and E) Mitochondrial dysfunction was measured by
an MTT assay under the same conditions described above. Bars represent the mean of three experiments 6 s.d. (**p,0.05). (C and F) Apoptotic cell
death was determined by flow cytometry with FITC Annexin V and DRAQ7. Data are representative results of three independent experiments.
doi:10.1371/journal.pone.0056881.g001
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140 mM NaCl, 2.5 mM CaCl2) and incubated with 10 ml FITC
Annexin V (BD Biosciences) and 10 ml of DRAQ7 (6 mM;
Biostatus) for 10 min at 37uC. Staining for Annexin V and
DRAQ7 was assessed by flow cytometry on a FC500 instrument
(Beckman Coulter) followed by data analysis using FlowJo software
(Tree Star Inc).
MTT mitochondrial dysfunction assay
Mitochondrial functionality was measured by a 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) col-
orimetric assay. Cells were cultured in sterile 96-well microtiter
plates at a seeding density of 1500 cells/well for the MEFS lines
and 2000 cells/well for HeLa cells. After seeding, cells were left to
adhere to the plate overnight, and then they were treated with the
compounds of interest and incubated at 37uC for 24 h. MTT
reagent (5 mg/ml in PBS) was added to each well and plates were
further incubated for 4 h at 37uC. Finally, the medium was
removed and the precipitated formazan crystals were dissolved in
optical grade DMSO. Plates were read at 570 nm on a Wallac
1420 workstation.
Trypan blue exclusion assay
Cells were seeded in 6-well plates at a cellular density of
1.56105 cells. After 24 h, cells were treated as described before.
Cells were detached and 0.5% trypan blue dye was added in
solution. Live cells possess intact cell membranes that exclude the
Figure 2. GX15-070 and CDDP induce caspase 3 independent cell death in Apaf-1 and Bax/Bak deficient cells. (A and D) Caspase 3-
like activity was measured in MEFS KO Apaf-1 and MEFS KO Bax/Bak treated with ABT737 (25 mM), GX15-070 (1 mM) and CDDP (30 mM) in the
presence or absence of QM31 (10 mM) and zVADfmk (5 mM). (B and E) Mitochondrial dysfunction was measured by an MTT assay under the same
conditions described above. Bars represent the mean of three experiments 6 s.d. (C and F) Apoptotic cell death was analyzed by flow cytometry
with FITC Annexin V and DRAQ7. Data are representative results of three independent experiments.
doi:10.1371/journal.pone.0056881.g002
Figure 3. Non apoptotic cell death upon CDDP treatment in Apaf-1- and Bax/Bak-deficient cells. (A) Cell survival was measured by
trypan blue exclusion upon treatment with CDDP (30 mM) in the presence or absence of necrostatin (Nec; 100 mM). Bars represent the mean of three
experiments 6 s.d. (**p,0.05). (B) MEFS wt Apaf-1, MEFS KO Apaf-1 and MEFS KO Bax/Bak were stained with DAPI upon CDDP (30 mM) treatment.
Nuclei are considered to have the normal phenotype when glowing bright and homogenously. Apoptotic nuclei can be identified by the fragmented
morphology of nuclear bodies. White arrows indicate dying cells.
doi:10.1371/journal.pone.0056881.g003
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dye, whereas dead cells do not. Unstained (viable) and stained
(non-viable) cells were counted separately in a hemacytometer and
the total number of viable cells in the population was calculated.
Nuclear staining
The cells cultured on coverslips were stained with 300 nM 49-6-
diamidino-2-phenylindole (DAPI) solution. The morphology of the
cells’ nuclei was observed using a fluorescence microscope (Leica
Vertical DM6000) at an excitation wavelength of 350 nm. Nuclei
are considered to have the normal phenotype when they glow
brightly and homogenously. Apoptotic nuclei can be identified by
either the condensed chromatin gathering at the periphery of the
nuclear membrane or a total fragmented morphology of nuclear
bodies.
Immunoblotting
Whole cell extracts were obtained by lysing cells in a buffer
containing 25 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM
EGTA, 1% SDS, plus protease and phosphatase inhibitors. The
protein concentration was determined by the BCA protein assay.
Cell lysates were resolved by SDS-PAGE, transferred to nitrocel-
lulose membranes, blocked with 5% non fat milk, washed with
0.1% Tween/PBS and incubated overnight with a specific
primary antibody. Membranes were washed and probed with
the appropriate secondary antibody conjugated to horseradish
peroxidase for enhanced chemiluminescence detection (Amersham
Pharmacia Biotech). The antibody against LC3 (#2775) came
from Cell Signaling and a-tubulin antibody (#T8203) was from
Sigma-Aldrich.
Statistical analysis
All the values represent the mean 6 s.d. of at least three
independent experiments. Statistical significance was determined
by one-way ANOVA using the Graph Pad software, p,0.05 was
designated as statistically significant.
Results and Discussion
Embryonic fibroblasts from wild-type mouse (MEFS wt Apaf-1
and MEFS wt Bax/Bak) [23] were treated with ABT737, GX15-
070 or cisplatin (cis-diammineplatinum(II) dichloride, CDDP),
either alone or in combination with apoptosome inhibitor
compound QM31 [19,20], or with broad spectrum caspase
inhibitor Z-Val-Ala-Asp(OMe)-fluoromethylketone (zVADfmk).
They were evaluated at 24 h post-treatment. ABT737 and CDDP
treatments induced activation of caspase-3, which was inhibited by
zVADfmk and by QM31. However, when cells were treated with
GX15-070, only residual caspase-3 activity was observed (Fig. 1A
and 1D). Cell viability was determined by MTT (Fig. 1B and 1E)
to find that ABT737- and CDDP-induced death (20% and 60%,
respectively) was inhibited by QM31, but not by zVADfmk, while
the cell death induced by GX15-070 (around 50%) was not
inhibited by either zVADfmk or QM31. Annexin V/DRAQ7 flow
cytometry assays corroborate viability and apoptotic cell death
Figure 4. Apaf-1 inhibition does not protect tumor HeLa cells
from death induced by ABT737 and GX15-070. (A) Caspase 3-like
activity was measured in the HeLa cells treated with ABT737 (25 mM),
GX15-070 (1 mM) and CDDP (30 mM) in the presence or absence of
QM31 (10 mM) and zVADfmk (5 mM). (B) Mitochondrial dysfunction was
measured by an MTT assay under the same conditions described above.
Bars represent the mean of three experiments 6 s.d. (*p,0.1;
**p,0.05). (C) Apoptotic cell death was analyzed by flow cytometry
with FITC Annexin V and DRAQ7. Data are representative results of
three independent experiments.
doi:10.1371/journal.pone.0056881.g004
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results (Fig. 1C and 1F). The same experiments were conducted in
Apaf-1 knockout (KO) mouse embryonic fibroblasts (MEFS KO
Apaf-1) [23], in MEFS KO Bax/Bak [22] and in cervix
adenocarcinoma cells (HeLa). In MEFS KO Apaf-1 (Fig. 2A)
and MEFS KO Bax/Bak (Fig. 2D), none of the treatments
induced caspase-3 activity, while cell viability was unaffected by
the ABT737 treatment, but decreased with both GX15-070 and
CDDP treatments (Fig. 2B and 2E). GX15-070- and CDDP-
induced cell death in these cells was not inhibited upon
apoptosome or caspase inhibition. Consequently, treatments with
Figure 5. GX15-070 promotes the activation of the autophagic pathway via LC3 in all the cell lines. (A–E) LC3 detection in MEFS wt
Apaf-1, MEFS wt Bax/Bak, MEFS KO Apaf-1, MEFS KO Bax/Bak and HeLa cells treated with ABT737 (25 mM), GX15-070 (1 mM), CDDP (30 mM ) and QM31
(10 mM).
doi:10.1371/journal.pone.0056881.g005
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QM31 and zVADfmk did not significantly modify the percentage
of Annexin V stained cells (Fig. 2C and 2F). These results suggest
that in the absence of key death-related cellular components, such
as the Bcl-2 proteins Bax and Bak and the apoptosome constituent
protein Apaf-1, ABT737-triggering signaling is not fully perceived
by the cell, while CDDP-depending signaling found caspase-
independent cell death pathways. CDDP-induced cell death was
partially recovered by necrostatin-1 (Nec), an inhibitor of RIPK1
in MEFS KO Apaf-1 and MEFS KO Bax/Bak (Fig. 3A),
suggesting that necroptosis (a form of programmed necrosis that
depends on activity of RIPK1) could participate in CDDP-induced
death in these cells. In fact, nuclear staining upon CDDP
treatment showed non apoptotic cell death in MEFS KO Apaf-1
and MEFS KO Bax/Bak cells (Fig. 3B), while treatment induced
canonical apoptotic bodies in MEFS wt Apaf-1, indicating that
DNA damaging agents may activate alternative cell death
pathways when the intrinsic pathway of apoptosis is blocked.
In human cervix adenocarcinoma (HeLa) cells, rather than
inducing caspase-3 activity, GX15-070 induced a type of cell death
that was not inhibited by zVADfmk or QM31 (Figs. 4A, 4B and
4C), which correlates with the phenotypes observed in all the
MEFS cell lines. CDDP induced caspase-3 activation, which was
inhibited in the presence of QM31 or zVADfmk, and also cell
death (Fig. 4A, 4B and 4C). CDDP-induced death was partially
prevented by QM31, but not by zVADfmk (Fig. 4B and 4C).
Nonetheless, the zVADfmk inhibition of ABT737-induced cas-
pase-3 activity was unable to protect cells from dying (Fig. 4B and
4C). Interestingly, and unlike the results found in the MEFS wt,
Figure 6. GX15-070 activates Beclin-1 non-dependent autophagy in all the cell lines. (A–D) LC3 immunoblotting in the MEFS wt Apaf-1,
MEFS KO Apaf-1, MEFS KO Bax/Bak and HeLa cell lines treated with rapamycin (30 mM) and GX15-070 (1 mM) for 24 h in the presence or absence of
3MA (10 mM).
doi:10.1371/journal.pone.0056881.g006
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apoptosome inhibition by QM31 did not inhibit ABT737-induced
caspase-3 and cell death (Fig. 4A and 4C).
To proceed with an initial analysis of the cell death pathway
induced by GX15-070 in the MEFS wt Apaf-1, MEFS wt Bax/
Bak, MEFS KO Apaf-1, MEFS KO Bax/Bak, and HeLa cells, we
analyzed the expression of anti-apoptotic proteins Bcl-2, Bcl-xL
and Mcl-1 and found no significant changes (data not shown). We
also explored the induction of autophagy. Autophagy is a catabolic
process involving the formation of autophagosomes and autolyso-
somes. Light chain 3 (LC3, a mammalian ortholog of yeast Atg8 -
[24]) is essential for autophagosome formation and can be used as
a reporter protein. When the process of autophagy proceeds, LC3-
I (the cytosolic form) it is processed to the autophagosomal
membrane-bound LC3-II form [24]. The LC3-II form increased
considerably with GX15-070 treatment (Fig. 5A–D), suggesting
that evaluated GX15-070-induced cell death was mediated by
autophagy activation in all the cell lines. The activity of III
phosphoinositide 3-kinase (PI3K III) is important in Beclin-1 (the
human ortholog of yeast Atg-6)-induced autophagy [25], and 3-
methyladenine (3MA – an inhibitor of PI3K III) is commonly used
to determine the dependence of Beclin-1 in autophagy. 3MA did
not modify GX15-070-induced LC3 processing (Fig. 6). Therefore,
GX15-070-induced autophagy in both MEFS wt and MEFS KO
Apaf-1 is independent of Beclin-1, as also reported for MEFS KO
Bax/Bak and HeLa cells [15]. As an internal control, we induced
autophagy by rapamycin and found that rapamycin-induced
autophagy was inhibited by 3MA in all four cell lines analyzed
(Fig. 6).
It has been reported that GX15-070 is able to induce apoptosis
and autophagy in several cell lines [26]. Thus we performed a
time-course analysis to examine whether GX15-070-treatment
induces both autophagy and apoptosis. We used LC3 conversion
as a marker of autophagy (Fig. 5) and caspase-3 activity as a
marker of apoptosis. After 24 h we did not observe GX15-070-
induced caspase-3 activation in the cell lines analyzed in the
present study (Fig. 7). At 48 h however, we noted that GX15-070-
induced caspase-3 activity in both MEFS wt and in HeLa cells.
GX15-070-induced apoptosis at 48 h was inhibited by apopto-
some inhibitor QM31. In contrast, GX15-070 did not induce
apoptosis in MEFS KO Bax/Bak and in MEFS KO Apaf-1 at
48 h. These results suggest that GX15-070 can induce multiple
cell death pathways, such as caspase-dependent apoptosis and
autophagy. Nevertheless, GX15-070-induced apoptosis is not only
dependent in Bax/Bak, as previously demonstrated [15,26], but
also in Apaf-1.
In conclusion, the present study reveals that BH3-mimetic
ABT737 not only requires Bax/Bak to exert its apoptosis-inducing
effect, but also Apaf-1, indicating the exclusive targeting of
ABT737 to Bcl-2 anti-apoptotic proteins. ABT737 upon binding
to Bcl-2 and Bcl-xL removes the anti-apoptotic activity of these
proteins in pro-apoptotic Bax/Bak and induces MOMP. Howev-
er, MOMP-dependent signaling needs the components of the
apoptotic pathway downstream of mitochondria, such as the
formation of the apoptosome, to induce cell death. Hence,
ABT737 treatments to cancer cells would have less side effects to
differentiated cells containing low levels of Apaf-1, such as neurons
and cardiomyocytes [27,28], than other treatments with lesser
dependence of Apaf-1. In contrast, BH3-mimetic GX15-070 and
DNA damage-inducing CDDP induce cell death in the absence of
both Bax/Bak and Apaf-1. While GX15-070 induces mainly
autophagy-based cell death at 24 h, a cell fraction dies by
apoptosis at longer times post-treatment. On the other hand,
CDDP induces necroptosis when apoptosis signaling pathway is
not available. Our results extend findings by describing not only
the sensitivity of different cells to the cell-inducing agents explored,
but also the behavior of current apoptosis inhibitors, which could
be useful in topical applications aimed to diminish unwanted cell
death. Non tumor cells, as demonstrated herein with MEFS wt,
could be protected from the cytotoxic effects of ABT737 and
CDDP by the chemical inhibition of the apoptosome through
QM31, which lowered caspase-3 activity and improved cell
survival, while the use of caspase inhibitors prevented caspase
activation, but did not improve survival. This scenario correlates
with proposals in mammals that solely caspase inhibition,
Figure 7. GX15-070 induces caspase 3-like activity after 48 h in HeLa and MEFs wt. Caspase 3-like activity was measured at 24 h and 48 h
upon treatment with GX15-070 (1 mM) in the presence or absence of QM31 (10 mM) in HeLa, MEFS wt Apaf-1, MEFS KO Apaf-1, MEFS wt Bax/Bak and
MEFS KO Bax/Bak.
doi:10.1371/journal.pone.0056881.g007
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downstream of MOMP delays, and in defined circumstances,
modifies the outcome rather than preventing cell death [29].
However, the autophagy-based cell death induced by GX15-070
was not prevented by QM31 or caspase inhibitors. These results
will be of interest when defining future combination therapies
where the systemic administration of cytotoxic agents, which aims
to kill malignant cells, could be locally counteracted by apoptosis
inhibitors. For instance, dermatopic and intra-cochlear adminis-
tration of apoptosome inhibitors would probably find applications
as anti-alopecia and anti-ototoxic agents, respectively, for anti-
cancer treatments based on ABT7373 and CDDP.
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